Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
AB Mauri (Uk) Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is being processed by 1 distinct examiner, indicating a concentrated prosecution effort for the company's current filings. The presence of 1 distinct art unit suggests that the company's intellectual property is currently focused within a specific technical niche of the biotechnology sector. Having only 1 pending office action allows the company to dedicate its resources to a single set of examiner concerns within this specialized field.
Russell G Fiebig is identified as the busiest examiner for the portfolio, with 1 pending office action currently under his review. Because there is only 1 pending office action in total, Fiebig is responsible for the full scope of the company's current interactions with the patent office. Practitioners should prepare for a focused dialogue with this specific examiner to resolve the outstanding Biotechnology & Pharmaceuticals matter efficiently. The outcome of the company's current prosecution efforts depends entirely on successfully addressing the requirements of the 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575677 | PHYSIOLOGICALLY ACCEPTABLE YEAST COMPOSITIONS FOR USE IN THE TREATMENT OF A GASTRO-INTESTINAL DISORDER | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575677 | PHYSIOLOGICALLY ACCEPTABLE YEAST COMPOSITIONS FOR USE IN THE TREATMENT OF A GASTRO-INTESTINAL DISORDER | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575677 | PHYSIOLOGICALLY ACCEPTABLE YEAST COMPOSITIONS FOR USE IN THE TREATMENT OF A GASTRO-INTESTINAL DISORDER | FIEBIG, RUSSELL G | 1655 | §103§112 | Non-Final OA | — | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial